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Abstract
Background: Leukocyte-mediated pulmonary inflammation is a key pathophysiological mechanism involved in
acute respiratory distress syndrome (ARDS). Massive sequestration of leukocytes in the pulmonary microvasculature
is a major triggering event of the syndrome. We therefore investigated the potential role of leukocyte stiffness and
adhesiveness in the sequestration of leukocytes in microvessels.
Methods: This study was based on in vitro microfluidic assays using patient sera. Cell stiffness was assessed by
measuring the entry time (ET) of a single cell into a microchannel with a 6 × 9–μm cross-section under a constant
pressure drop (ΔP = 160 Pa). Primary neutrophils and monocytes, as well as the monocytic THP-1 cell line, were
used. Cellular adhesiveness to human umbilical vein endothelial cells was examined using the laminar flow
chamber method. We compared the properties of cells incubated with the sera of healthy volunteers (n = 5),
patients presenting with acute cardiogenic pulmonary edema (ACPE; n = 6), and patients with ARDS (n = 22), of
whom 13 were classified as having moderate to severe disease and the remaining 9 as having mild disease.
Results: Rapid and strong stiffening of primary neutrophils and monocytes was induced within 30 minutes (mean
ET >50 seconds) by sera from the ARDS group compared with both the healthy subjects and the ACPE groups
(mean ET <1 second) (p < 0.05). Systematic measurements with the THP-1 cell line allowed for the establishment of
a strong correlation between stiffening and the severity of respiratory status (mean ET 0.82 ± 0.08 seconds for
healthy subjects, 1.6 ± 1.0 seconds for ACPE groups, 10.5 ± 6.1 seconds for mild ARDS, and 20.0 ± 8.1 seconds for
moderate to severe ARDS; p < 0.05). Stiffening correlated with the cytokines interleukin IL-1β, IL-8, tumor necrosis
factor TNF-α, and IL-10 but not with interferon-γ, transforming growth factor-β, IL-6, or IL-17. Strong stiffening was
induced by IL-1β, IL-8, and TNF-α but not by IL-10, and incubations with sera and blocking antibodies against IL-1β,
IL-8, or TNF-α significantly diminished the stiffening effect of serum. In contrast, the measurements of integrin
expression (CD11b, CD11a, CD18, CD49d) and leukocyte–endothelium adhesion showed a weak and slow response
after incubation with the sera of patients with ARDS (several hours), suggesting a lesser role of leukocyte
adhesiveness compared with leukocyte stiffness in early ARDS.
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Conclusions: The leukocyte stiffening induced by cytokines in the sera of patients might play a role in the
sequestration of leukocytes in the lung capillary beds during early ARDS. The inhibition of leukocyte stiffening with
blocking antibodies might inspire future therapeutic strategies.
Background
Acute respiratory distress syndrome (ARDS) has been
identified as a bilateral pulmonary inflammatory condi-
tion that follows direct or indirect lung injury [1]. Rigor-
ous clinical management has not reduced the mortality
of ARDS to <30 % [2], mainly owing to a lack of under-
standing of ARDS pathophysiology. The sequestration of
leukocytes, particularly neutrophils, in the lung micro-
vasculature [3] appears to be a key determinant of the
pathophysiology of ARDS, leading to blood circulation
blockage, microthrombus formation [4, 5], uncontrolled
inflammation, and injury to the alveolar–capillary mem-
brane [1]. Researchers have attempted to clarify the
mechanisms involved in leukocyte sequestration in many
studies. Changes in leukocyte adhesion to vessel walls
have been reported in various inflammation contexts
[6–9], notably in ARDS [9]. In vitro studies [10, 11]
have also shown that a fraction of circulating leuko-
cytes of patients with ARDS, as well as patients with
sepsis, trauma, and pneumonia, resulted in impaired
deformability most likely caused by the densification
of F-actin in the cortical region [6, 10], suggesting a
role of leukocyte stiffening in sequestration of leukocytes
in lung capillaries [4]. However, the roles of leukocyte
adhesion and stiffness remain unclear. Microcirculation
impairments have been associated with abnormal concen-
trations of cytokines and endotoxins in various inflamma-
tory diseases [8–19], but the case of ARDS has rarely been
studied. Moreover, consensus conclusions have been diffi-
cult to draw due to the diversity of experimental condi-
tions and models. For instance, some studies have failed
to show any effect of interleukin (IL)-8 on leukocyte stiff-
ness [12, 19], whereas others have found a pronounced
effect [16]. Additionally, IL-8 and tumor necrosis factor
(TNF)-α have been reported to promote adherence in
some conditions [12], whereas no effects have been de-
tected in other studies [8, 20]. Altogether, it appears that
the triggering events of ARDS, mainly leukocyte seques-
tration in the lungs, remain largely obscure with regard to
the mechanisms and biochemical signaling involved.
In the present study, using in vitro microfluidic me-
thods, we investigated leukocyte stiffness and adhesive-
ness in response to incubation in the sera of patients
with ARDS. The time required for a leukocyte to pene-
trate a synthetic microchannel allowed us to assess the
stiffness of the leukocytes, whereas a laminar flow cham-
ber assay was used to characterize their adhesiveness.
The main objectives of this study were first to demon-
strate that the sera of patients with ARDS induced
leukocyte stiffening and then to identify the cytokine




This prospective, observational study was conducted in
the medical intensive care unit (ICU) of a teaching
hospital. The investigation was approved by the local eth-
ics committee of the Assistance Publique-Hopitaux de
Marseille. All consecutive mechanically ventilated patients
presenting with ARDS, as defined according to the Berlin
definition [21], were included when they were early in the
course of the disease. Within 2 days of ARDS onset, the
lower ratio of partial pressure of oxygen in arterial blood
to fraction of inspired oxygen (PaO2/FiO2) was measured
and used to classify the patients with ARDS according to
the Berlin definition. Patients with PaO2/FiO2 ratios
<200 mmHg were assigned to the moderate to severe
ARDS group, and patients with a PaO2/FiO2 ratio between
200 and 300 mmHg were assigned to the mild ARDS
group. Volume assist control ventilation was used with a
tidal volume of 6–8 ml/kg of predicted body weight and a
maximal plateau pressure of 32 cmH2O. The oxygenation
goal was a pulse oximetry–measured arterial oxygen sat-
uration of 88–95 % or a PaO2 of 55–80 mmHg, with the
FiO2 and positive end-expiratory pressure adjusted as in
the ARMA trial [22]. Five healthy volunteers from our
medical department served as the healthy group. Six
mechanically ventilated patients with acute cardiogenic
pulmonary edema (ACPE) were also enrolled as the ACPE
group. Septic shock (SS) was defined in accordance with
the 2001 Society of Critical Care Medicine/European
Society of Intensive Care Medicine/American College of
Chest Physicians/American Thoracic Society/Surgical
Infection Society International Sepsis Definitions Confer-
ence criteria [23]. Patients presenting with immunological
treatment, neoplasia, and corticosteroid treatments were
not included.
To assay IL-6, 1 ml of serum was obtained from sys-
temic arterial blood samples taken during the usual med-
ical care of patients in the ICU. Blood samples were
obtained from patients with ARDS and patients with
ACPE within the first 48 h following the onset of the lung
insult, and the samples were stored at −80 °C. Serum
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samples were also obtained from five healthy volunteers
and were stored at −80 °C.
Investigation strategy
The changes in the distribution of cell stiffness induced
in a leukocyte population by serum incubation were
assessed by taking systematic measurements of the
leukocyte entry times (ETs) into a microfluidic constric-
tion. The stiffening effects of the sera of patients with
ARDS were first tested on primary neutrophils and
monocytes. Then THP-1 cells were used for a systematic
study of sera from the healthy volunteers and the ACPE
and ARDS groups. To identify the cytokines potentially
involved in cell stiffening, we correlated the mean ET for
all of the subjects in the three groups with the cytokine
levels in their sera. Recombinant cytokines were further
used to confirm and quantify the stiffening potential of
the relevant cytokines. Finally, cytokine-blocking anti-
bodies (Ab) were added to the sera to analyze the re-
spective involvement of the cytokines in the stiffening
effects of the patients’ sera and to test for protective ef-
fects against the pathological stiffening effects of the pa-
tients’ sera.
Microfluidic protocol to characterize the distribution of
cell stiffness
The protocol [24] is depicted in Figure S1 (see Additional
file 1). Cells incubated in sera were directed into micro-
fluidic circuitry by varying the height of the macroscopic
reservoirs (Additional file 1: Figure S1a) connected to a
microfluidic chip positioned on a microscope stage
(Additional file 1: Figure S1b). The ET into a micro-
fluidic constriction is known to be a good indicator
of cell stiffness [14, 25]. However, devices with a sin-
gle constriction have been found to be poorly adapted
for cells of elevated stiffness because the mismatch
between the rectangular cross-section of microfluidic
channels and the spherical shape of the cells allows
for flow leakage around the cells (Additional file 1:
Figure S1c[i]) and induces poor ET reproducibility.
The device used in this study had two constrictions
in series, C1 and C2, of similar width (W = 6 μm) and
with heights of H1 = 12 μm and H2 = 9 μm, respectively
(Additional file 1: Figure S1d, e). A cell was first forced
into constriction C1, where it occupied the entire cross-
section of the channel and therefore prevented leaks in
corners (Additional file 1: Figure S1c[ii]). Cell stiffness was
then assessed by examining the cell’s passage from con-
striction C1 into the narrower constriction C2. The ET of
each single cell was determined by examining video
microscopy sequences as the time interval between
the leading edge of the cell touching the entrance of
constriction C2 and the trailing edge of the cell clearing
the entrance of constriction C2 (Additional file 1: Figure
S1c[iii], c[iv]).
Microfabrication
Microfluidic devices were fabricated using standard soft
lithography procedure [26]. A positive mold was created
with SU-8–negative resins (MicroChem, Westborough,
MA, USA) on silicon wafers (Sil’Tronix, Archamps,
France). Replicas were made in polydimethylsiloxane
elastomer (SYLGARD® 184; Dow Corning, Auburn, MI,
USA) and were sealed on glass cover slides via plasma
activation (Harrick Plasma, Ithaca, NY, USA). The
channels were incubated with a 1 % Pluronic F 108
solution (BASF, Florham Park, NJ, USA) for 1 h to
deter cell adhesion. Observations were made using an
inverted microscope (Axio Observer 200; Carl Zeiss
Microscopy, Oberkochen, Germany) equipped with a
phase contrast objective (Plan-Neofluar 100×/1.30 Oil
Ph3; Carl Zeiss Microscopy) and a Burle TC65 cam-
era (Burle).
Cell preparation
Primary monocytes and neutrophils were isolated from
whole blood and were analyzed within 3 h. Whole blood
was collected in heparin vials from healthy donors who
provided informed consent. For cell stiffness measure-
ments, polymorphonuclear cells and peripheral blood
mononuclear cells (PBMCs) were separately isolated
from whole blood by gradient density centrifugation
using Histopaque-1077 solution (Sigma-Aldrich, St. Louis,
MO, USA). Monocytes were separated from the PBMC
fraction by negative selection using the Pan Monocyte
Isolation Kit, human (Miltenyi Biotec, Bergisch Gladbach,
Germany). Red blood cells were eliminated from the poly-
morphonuclear fraction via hypotonic lysis. The mono-
cytic THP-1 cell line (American Type Culture Collection,
Manassas, VA, USA) was maintained in Gibco RPMI 1640
medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 10 % fetal calf serum and 2 mML-glutamine.
Incubations of cells with patients’ sera were performed for
1 h at 10 %. Cytoskeleton inhibition was performed with
latrunculin A (Molecular Probes, Eugene, OR, USA) at
3 μg/ml and nocodazole (Sigma-Aldrich) at 5 μg/ml for
30 minutes. For the cytometric analysis, we used CD3,
CD14, and CD66b Ab to control the efficacy of T lympho-
cyte, monocyte, and neutrophil purification procedures.
Neutrophils were isolated from whole blood by negative
selection using the EasySep™ Direct Human Neutrophil
Isolation Kit (STEMCELL Technologies, Vancouver, BC,
Canada). Monocytes were isolated from PBMC fractions
by negative selection using the Pan Monocyte Isolation
Kit, human (Miltenyi Biotec). Lymphocytes were studied
using the PBMC fraction.
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Monoclonal antibodies
The following adhesion function-blocking Ab against hu-
man adhesion molecules were used: anti-L-selectin
(CD62L), anti-αL chain integrin (CD11a), anti-integrin β1
(CD29), anti-αM chain of Mac-1 integrin (CD11b), α4
chain of VLA-4 integrin (CD49d), and anti-β2 chain of
lymphocyte function-associated antigen 1 integrin (CD18)
(all from BioLegend, San Diego, CA, USA). To discrimin-
ate cells in the cytometry data, we also used Ab
against CD3, CD14, and CD66b (BioLegend). The fol-
lowing Ab against cytokines were used: anti-IL8 and
anti-IL10 (AbD Serotec, Raleigh, NC, USA) and anti-
TNF-α (Janssen Biologics BV, Leiden, the Netherlands).
We also used Ab for control experiments: anti-mouse
immunoglobulin G1 (IgG1) (AbD Serotec), mouse IgG1
(eBioscience, San Diego, CA, USA), human polyclonal Ab
(LFB Biomedicaments, Ulis, France), and goat IgG1 (AbD
Serotec).
Reagents
Enzyme-linked immunosorbent assay (ELISA) kits for
testing human TNF-α, interferon (IFN)-γ, transforming
growth factor-β1, IL-1β, IL-6, IL-8, IL-10, and IL-17 were
obtained from R&D Systems (Minneapolis, MN, USA).
Recombinants of IL-8, TNF-α, and IL-10 were purchased
from Life Technologies, and recombinants of IL-1β were
purchased from PeproTech (Rocky Hill, NJ, USA).
Cytometric and adhesion measurements
Cytometric measurements were performed with a BD LSR
II flow cytometer (BD Biosciences, San Jose, CA, USA).
Labeling was performed according to the manufacturer’s
recommendations. Adhesion between circulating leuko-
cytes and model endothelium were examined in vitro
using the laminar flow chamber technique and human
umbilical vein endothelial cells (PromoCell, Heidelberg,
Germany) [27]. Cells were pushed by horizontal flow and
sedimented by gravity in the vicinity of the endothe-
lial cell monolayer cultured to confluence on a glass
substrate coated with fibronectin. The frequencies of
cell arrests under constant hydrodynamic shear stress
were monitored.
Statistical analysis
The distribution was evaluated using the Kolmogorov-
Smirnov test. According to the variable distributions,
differences between groups were assessed using one-way
analysis of variance (with post hoc Tukey’s test), Stu-
dent’s t tests, the Mann-Whitney U test, Wilcoxon’s test,
or Fisher’s exact test. The correlations between ETs and
cytokine concentrations were assessed using Spearman’s
test. A p value <0.05 was considered significant. All of
the reported p values are two-sided. If not mentioned,
statistical analysis was conducted using IBM SPSS ver-
sion 20.0 software (IBM, Armonk, NY, USA). Graphs
were created using GraphPad Prism software (GraphPad
Software, La Jolla, CA, USA).
Results
Patients
Twenty-two patients who presented with early ARDS
were included. Thirteen patients were classified in
Table 1 Patient characteristics
Characteristics Healthy (n = 5) ACPE (n = 6) Mild ARDS (n = 9) Moderate/severe ARDS (n = 13)
Age, yr 38 [34–43] 72 [68–82] 57 [42–71] 58 [56–76]
Sex, M/F, n 2/3 3/3 4/5 9/4
Septic shock, n – – 5 10
SAPS II at admission – 24 [21–26] 52 [49–57] 53 [46–57]
PaO2/FiO2,
a mmHg – 145 [130–201] 220 [202–223] 105 [98–122]
PEEP,a mmHg – 5 [5–7] 5 [5–7] 8 [8–12]
Lung Injury Scorea – – 1.5 [1.25–1.75] 2.25 [2–2.25]
Causes of ARDS/ALI, n
Direct – – 6 8
Pneumonia 5 7
Gastric inhalation 1 1
Indirect – – 3 5
Pancreatitis 2 2
Intra-abdominal infection 1 3
ACPE acute cardiogenic pulmonary edema, ALI acute lung injury, ARDS acute respiratory distress syndrome, FiO2 fraction of inspired oxygen, PaO2 partial pressure
of oxygen in arterial blood, PEEP positive end-expiratory pressure, SAPS II Simplified Acute Physiology Score II
Results are expressed as median [IQR] unless otherwise indicated
aLower PaO2/FiO2 ratio during the first 48 h
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the moderate to severe ARDS group, and 9 patients
were included in the mild ARDS group. Among pa-
tients with ARDS, 15 patients presented with associ-
ated SS. The patient characteristics are summarized
in Table 1.
Serum of patients with ARDS induced leukocyte stiffening
A typical measurement with the microfluidic stiffness
tester is presented in Fig. 1a-c (see Additional file 2 for
an additional movie file showing this in more detail).
THP-1 cells incubated with healthy serum (Fig. 1d) were
characterized by a log-normal distribution, whereas
ARDS serum incubated THP-1 cells (Fig. 1e) had greatly
widened distributions with two populations of roughly
similar size: one population of moderately stiffened cells,
with ETs one order of magnitude greater than healthy
cells (2 < ET < 5 seconds), and another population of
highly stiff cells with ETs up to two orders of magni-
tude greater than healthy cells (15 < ET < 100 seconds).
This double population distribution was a general
Fig. 1 Microfluidic assay of leukocyte stiffness. a–c Leukocyte (THP-1) entering the microfluidic stiffness tester (a) represented on a schematic and
(b) and (c) observed by video microscopy for a local suction pressure ΔP = 160 Pa, and after 1-h incubation with the serum (b) of a healthy
volunteer and (c) of a patient with moderate to severe acute respiratory distress syndrome (ARDS). The green arrows indicate the entry of constriction
C2. (i) Cell entering the funneled constriction C1, (ii) early cell contact with the entrance of constriction C2, (iii) the development of a cell projection in
constriction C2, and (iv) completed entry in constriction C2. The scale bar represents 20 μm, the timing origin corresponds to first contact of the cell
with entry of C2, and the entry time (ET) corresponds to the time for completed entry of a cell in C2 (see movie 1 in Additional file 2). d and e Cells
stiffened by sera of patients with ARDS are distributed in two populations. Cumulative fraction of ET at ΔP = 160 Pa for THP-1 cells (d) incubated in
serum of a healthy donor (filled circles) with a fit by a log-normal (Ln) distribution with μ = 0.8 and σ2 = 3.7 s2 (black line) and (e) incubated with the sera
of three patients with moderate to severe ARDS (open symbols). All cells are stiffened and distributed in a bimodel population of moderately and highly
stiffened cells. For each patient serum sample, the numbers of tested cells were 250 in (d) and 50 in (e)
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feature of ARDS serum incubated cells. In primary
fresh neutrophils and monocytes, as in THP-1 line
cells (Fig. 2), sera of patients with ARDS induced
rapid and intense stiffening, showing that the stiffen-
ing effect of the sera of patients with ARDS acted on
all leukocytes.
Leukocyte stiffening was associated with ARDS severity
Compared with the sera of healthy subjects, the sera
of patients with ACPE did not affect THP-1 stiffening
(Fig. 3a), whereas the sera of patients with mild or
moderate to severe ARDS increased the ETs of THP-
1 cells. Hence, the sera of patients with ARDS in-
duced leukocyte stiffening, whereas cardiogenic edema
was not a relevant parameter in this process. This
finding supports the hypothesis that leukocyte stiffen-
ing induced by serum is related to the severity of
lung injury due to ARDS.
Leukocyte stiffening effects were associated with lung injury
To evaluate the respective roles of ARDS and SS, we
compared the ETs between patients presenting with
ARDS without SS and patients presenting with ARDS
with SS. As shown in Fig. 3b, the group of patients pre-
senting with ARDS with SS had higher ETs than the
group presenting with ARDS without SS. However, the
group of patients with ARDS and without SS showed
significantly higher ETs than the healthy subjects and
patients with ACPE (p < 0.0025). This finding demon-
strates a specific link between ARDS and leukocyte stiff-
ening, independent of the presence of SS.
IL-1β–, IL-8–, and TNF-α–induced leukocyte stiffening
The serum levels of cytokines are reported in Additional
file 1: Table S1. We found positive correlations between
the ETs and the cytokine levels of IL-1β, IL8, IL-10, and
TNF-α (see Additional file 1: Figure S2). Figure 4a shows
that recombinant IL-1β, IL-8, and TNF-α (at the max-
imum concentration found in the patient sera) each in-
duced a pronounced stiffening of THP-1 cells, whereas
IL-10 had no significant effect. Furthermore, incubation
of THP-1 cells with recombinant IL-1β, IL-8, or TNF-α
and with a large excess of blocking Ab anti-IL-1β, anti-
IL-8, or anti-TNF-α did not affect cell stiffness compared
with that of the controls without cytokines and Ab.
Partial reversal of serum-induced stiffening by antibodies
against IL-1β, IL-8, and TNF-α
We incubated THP-1 cells with sera from patients with
ARDS and blocking Ab against cytokines (Fig. 4b). An
excess of blocking Ab against IL-1β, IL-8, and TNF-α
markedly reduced serum-induced stiffening, whereas the
blocking Ab against IL-10 had no effect. These results
proved that IL-1β, IL-8, and TNF-α participated signifi-
cantly in the leukocyte stiffening effect induced by the
sera of patients with ARDS. Nevertheless, cells protected
by the three blocking Ab remained significantly stiffer
than the control cells, suggesting that IL-1β, IL-8, and
TNF-α were not the only factors in the stiffening process
induced by sera or that synergistic effects might exist.
Mixtures of IL-8 and TNF-α at 1000 pg/ml and 20 pg/ml,
respectively, did not induce significant synergistic effects
compared with isolated components.
Role of adhesion
Figure 5 presents the adhesion frequency of THP-1 cells
on monolayers of endothelial cells. There were no de-
tectable changes in adhesion frequencies for ACPE and
ARDS without SS, whereas an increase in the frequency
was observed in ARDS with SS. Adhesion measurements
under flow suggested that the increased adhesion was
related to SS rather than to ARDS.
Integrin receptor expression by incubations in patient
sera is nonsignificant
The expression of surface receptors (CD62L, CD11a,
CD11b, CD18, and CD49d) was found to be roughly
similar for the groups of healthy donors and patients
with ARDS after incubations for 1 h and 24 h for lympho-
cytes and monocytes, and for 1 h and 4 h for neutrophils
(Fig. 6). Even sera of patients with SS did not induce
significant upregulation of surface receptors at the same
Fig. 2 Serum of a patient with acute respiratory distress syndrome
(ARDS) induced stiffening on primary monocytes and neutrophils.
Entry times (ETs) measured for THP-1 cells (open bar), primary monocytes
(black bars), and primary neutrophils (gray bars) after 1-h incubation with
the sera of a healthy donor and of a patient with ARDS. The number of
tested cells per condition was >30. Values are mean ± standard deviation.
*p < 0.05; ***p < 0.0001 (Mann-Whitney U test). For neutrophils
incubated in serum of patients with ARDS, cells never completed
their entry in C2 at 300 seconds and experiments were stopped. ETs
are reported as >300 seconds, and there is no error bar
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concentration of 10 % serum in RPMI medium that was
also used for the stiffening experiments.
Actin cytoskeleton and stiffening
The incubation of cells with the actin polymerization
inhibitor latrunculin A was found to inhibit serum-
induced stiffening to a great extent, whereas the tubulin
polymerization inhibitor nocodazole had a negligible
impact (see Additional file 1: Figure S3). The results
suggested that cell stiffening was actin-dependent.
Discussion
In the present study, we have shown that the serum of
patients with ARDS induced rapid and intense actin-
dependent stiffening of leukocytes. This leukocyte stiff-
ening was associated with the severity of ARDS. The low
expression of adhesion molecules of the integrin family
suggested that leukocyte stiffening plays a more import-
ant role than adhesiveness in their sequestration in the
lung microvasculature in the early phase of ARDS. Ana-
lysis of serum composition and the use of recombinant
cytokines showed that cytokines IL-1β, IL-8, and TNF-α
were major contributors to leukocyte stiffening by the
sera of patients with ARDS. Finally, blocking Ab against
IL-1β, IL-8, and TNF-α was found to protect leukocytes
from serum-induced stiffening.
Various methods have been employed to evaluate
leukocyte deformability, but there is no standard tool for
clinical applications. Microfiltration experiments, such
as cell transit analysis, have been used to study sepsis
and lung injury [10, 18], but the transit times of cell
suspensions through micropore filters remain qualitative
and cannot distinguish between the effects of adhesiveness
or stiffness, because both are possible in these assays.
Conversely, single-cell methods, such as micropipette as-
piration [19], cell poker [15, 25], or atomic force micros-
copy [14], allow for precise mechanical measurements,
but their throughput is too low for medical studies. The
strategy of using microfluidics allows one to design
higher-throughput experiments [14, 25] for adhesiveness
or stiffness and to mimic the targeted physiological condi-
tions of the geometry (approximately 6 μm) and pressure
(about 100 Pa) of the lung microvasculature, as was done
in the present study.
Fig. 3 a Stiffness vs. lung injury. Distributions of the median entry times (ETs) measured after 1-h incubation of THP-1 cells with the sera of
healthy donors (control; n = 5), patients with acute cardiogenic pulmonary edema (ACPE; n = 6), patients with mild acute respiratory distress
syndrome (ARDS; n = 9, among whom 5 had septic shock [SS]), and patients with moderate to severe ARDS (n = 13, among whom 10 had septic
shock). b Stiffness vs. SS. Distributions of the median ETs measured after 1-h incubation of THP-1 cells with the sera of healthy subjects (n = 5),
patients with ACPE (n = 6), patients with ARDS but without septic shock (n = 7), and patients with both ARDS and septic shock (n = 15). The
number of tested cells per patient was 50. Box plots represent the median (black bar inside box), interquartile range (box), and minimum and
maximum values (whiskers). *p < 0.05; **p < 0.0025; ***p < 0.0001 (Mann-Whitney U test)
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We chose to study the stiffening of leukocytes using
THP-1 cells, mainly because this cell line, but not freshly
isolated primary neutrophils, allows for the establish-
ment of a stable and reproducible analysis protocol. The
relevance of using monocytes and a cell line to analyze
ARDS mechanisms is arguable. However, researchers in
some studies have reported evidence of neutrophil-
independent mechanisms of ARDS [28, 29], supporting
nonnegligible roles of other types of leukocytes and sug-
gesting that monocytes indeed contribute substantially to
neutrophil recruitment in lungs during pulmonary inflam-
mation and injury in mouse models [30, 31]. Additionally,
the THP-1 cell line as a model was supported by the
strong similarities of these cells to monocytes with regard
to migration stimulated by N-formylmethionyl-leucyl-
phenylalanine [32], phospholipase D activation of ad-
hesion [33], increase in the mechanical strength of
adhesion to endothelial cells induced by monocyte
colony-stimulating factor [34], stimulation with cor-
onavirus responsible for an ARDS-like syndrome [35],
and the binding of chemotactic factors to THP-1 cells
and neutrophils [36]. Finally, we showed that the stiffening
effects of the sera of patients with ARDS were ubiquitous
on THP-1 cells, monocytes, and neutrophils.
Abnormal leukocyte stiffness has been reported in previ-
ous studies of SS and ARDS [4, 6, 10–12, 14, 18], but our
data provide the first evidence, to the best of our
knowledge, that leukocyte stiffening is an intrinsic charac-
teristic of ARDS, independent of the presence of SS or car-
diogenic pulmonary edema. To the best of our knowledge,
the investigators in the only study in which leukocyte stiff-
ness during ARDS was measured [12] reported that
leukocyte populations were moderately stiffened and that
very few cells (<5 %) had extremely high stiffness. We also
found a bimodal distribution, but interestingly the popula-
tion of highly stiff cells represented, in our data, approxi-
mately 50 % of all of the cells. This finding suggested that
the earlier study of patients’ cells [12] could have been
biased by the trapping of the stiffest cells in the patients’
microvasculature, whereas our serum-based findings, with
a large proportion of more stiffened cells, would be more
representative of patients’ whole leukocyte populations.
Our study is also the first to demonstrate leukocyte stiff-
ening induced by incubation with the sera of patients with
ARDS. The serum stiffening effect was rather rapid (<1 h),
compatible with a role in the early triggering of leukocyte
sequestration in the microvasculature. In the end, the
associations of the severity of ARDS with leukocyte stiff-
ening and the presence of leukocyte stiffening independ-
ent of SS support an intrinsic role for leukocyte stiffness
in the pathogenesis of lung injury.
Regarding leukocyte adhesion evaluated by the expression
of integrin receptors, the literature shows a very limited and
rather slow upregulation of adhesion molecules in the
Fig. 4 a The effect of cytokine recombinants on THP-1 stiffness. Entry times (ETs) measured after 1-h incubation of THP-1 cells with interleukin
(IL)-8, tumor necrosis factor (TNF)-α, IL-1β, and IL-10 at 1000 pg/ml, 20 pg/ml, 10 pg/ml, and 200 pg/ml, respectively, without (gray bars) or with
(open bars) 1 μg/ml anti-IL-8, anti-TNF-α, anti-IL-1β, and anti-IL-10 antibodies (Ab), respectively. The black bar represents control cells without
cytokines and Ab. b The effect of serum of patients with acute respiratory distress syndrome (ARDS) with blocking Ab of IL-8, TNF-α, and IL-1. ETs
measured after 1-h incubation of THP-1 cells with the serum of patients with ARDS, without (gray bars) and with (open bars) 1 μg/ml of anti-IL-8,
anti-TNF-α, anti-IL-1β, and anti-IL-10 Ab. The black bar corresponds to control cells without patient serum and Ab. The number of tested cells per
incubation condition was 50. Values are the mean (top of box) ± standard deviation (whiskers). **p < 0.0025; ***p < 0.0001 (Student’s t test)
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plasma of patients with sepsis (e.g., CD49d for neutrophils)
[8–10]. With our samples and with similar incubation con-
ditions, faint effects of adhesion molecule upregulation
were not detectable, whereas cell stiffening was found to
be fast and strong. This finding suggests that circulat-
ing factors might favor leukocyte adhesion, but only
after a delay of several hours. Interestingly, adhesion, as
shown by laminar flow experiments after exposure to
ARDS sera, was not significantly increased, further dem-
onstrating that adhesion might not play a major role in
early ARDS. In the end, one could conclude that leukocyte
arrest in the microvasculature in ARDS might be triggered
by rapid leukocyte stiffening at early time points
(within 1 h), whereas adhesiveness may develop at later
stages. Interestingly, similar scenarios have previously
been proposed for other pathologies [37–39].
Increased IL-6 was reported in patients with sepsis
and leukocyte sequestration [9], as in our data. However,
we found no correlation between IL-6 and leukocyte
stiffening, suggesting that the role of IL-6, if any, is not
dominant. Indeed, leukocyte stiffening appeared in vitro
at IL-6 concentrations >10,000 pg/ml [20], which is
much higher than the content in the sera of our patients
with ARDS. We found that TNF-α, IL-1β, and IL-8
induced leukocyte stiffening. Similar effects were re-
ported for TNF-α and IL-1β at concentration thresholds
>100 pg/ml [13, 20]. We showed a significant stiffen-
ing effect at <10 pg/ml for IL-1β and at 20 pg/ml for
TNF-α. For IL-8, previous researchers have reported no
effects [13, 20] at 10,000 pg/ml and a transient (1 h) effect
at 1000 pg/ml [17]. We found strong stiffening within 1 h
with IL-8 at only 1000 pg/ml. Our experiments with Ab
confirmed the direct participation of these three cytokines
in the stiffening effect of serum, as monoblockade of IL-
1β, IL-8, or TNF-α significantly reduced the effect. How-
ever, our results with pure recombinants and with sera
mixed with Ab against each cytokine suggested that other
substances, which remain to be identified, played additive
and/or synergistic roles.
There is not yet any therapeutic treatment to reverse
abnormal leukocyte stiffening. Cytochalasin D is efficient
but has a systemic toxicity. Pentoxifylline, a phospho-
diesterase inhibitor, reduces neutrophil stiffening, but its
efficacy for treating hemorrhagic shock has been found
to be very limited [14, 40]. Blocking Ab against TNF-α
provided weak prophylactic and poor therapeutic effects
in large cohorts of patients with sepsis [37]. Never-
theless, patients with sepsis and lung injury might
benefit from the blockade of multiple cytokine path-
ways because researchers in recent studies of mice
and humans have reported beneficial responses in
cases of acute lung injury [38] and sepsis [39]. Our
results regarding protection against stiffening by
blocking Ab support the exploration of cytokine regula-
tion for therapeutic purposes. Previous unsuccessful clin-
ical assays have been based on long-term treatments, and
future assays could benefit from regular monitoring of
leukocyte stiffness during treatment with a microfluidic
tool to adjust the treatment dose and time. This rationale
would also be helpful for other therapeutic approaches,
such as treatment with sivelestat, a neutrophil elastase in-
hibitor that limited leukocyte stiffening in vitro [18], bene-
fited pulmonary function [41], and improved the survival
of patients with ARDS with sepsis [42].
Conclusions
We have shown that the serum of patients with ARDS
induced rapid and intense actin-dependent stiffening of
leukocytes. This leukocyte stiffening was associated with
the severity of ARDS. The low induction by patient sera
of adhesion to endothelial cells and of upregulation of
adhesion molecules suggested that leukocyte stiffening
plays an important role in their sequestration in the lung
microvasculature in the early phase of ARDS. Stiffening
was in large part induced by increased levels of IL-1β,
IL-8, and TNF-α in the sera of patients with ARDS. Ab
against these three cytokines protected leukocytes from
the serum-induced stiffening.
Fig. 5 Leukocyte–endothelium adhesion. The frequency of arrest per
unit length of THP-1 cells flown at a shear rate of 9.6/second on top
of a confluent human umbilical vein endothelial cell layer after 24-h
incubation with the sera of healthy donors, patients with acute
cardiogenic pulmonary edema (ACPE; n = 6), patients with acute
respiratory distress syndrome (All ARDS; n = 22), patients with ARDS
but without septic shock (ARDS W/OSS; n = 7), and patients with
both ARDS and SS (ARDS with SS; n = 15). Values are mean ± standard
error of the mean. The number of tested cells was >200 per patient.
*p < 0.05 ; **p < 0.0025 (Student’s t test)
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Key messages
 The sera of patients with ARDS induced rapid and
intense actin-dependent leukocyte stiffening.
 The relationship between leukocyte stiffening and
the severity of ARDS suggests a role for leukocyte
stiffening in ARDS pathophysiology.
 Stiffness, rather than adhesiveness, might play an
important role in leukocyte sequestration in early
ARDS.
 IL-1β, IL-8, and TNF-α are major contributors to
leukocyte stiffening in ARDS sera.
 Blocking Ab against IL-1β, IL-8, and TNF-α was
shown to protect leukocytes from stiffening in sera.
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Fig. 6 The expression of adhesion molecules. Cytometry data for
human (a) primary neutrophils, (b) monocytes and (c) lymphocytes.
The graph report the (MFI) for CD11a, CD11b, CD18, CD62L, CD49d,
CD29 measured with healthy donors and ARDS patient samples at 1
and 4h for neutrophils, and at 1 and 24 h for monocytes and
lymphocytes. The number of samples for healthy donors (n = 10)
and patients with ARDS (n = 22). MFI values are the mean +/- SD.
Mann-Whitney p-values are all > 0.05 between healthy donors and
ARDS patients
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